Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Maria M Haykal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Universi…. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Breast Neoplasms, Protein-Tyrosine Kinases, Nuclear Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: La Ligue Contre Le Cancer, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale.
Abstract (Originalsprache)
ATIP3-deficient breast cancers represent a subset of aggressive tumors with limited therapeutic options and poor prognosis. Here, we screened a panel of cell cycle kinase inhibitors to identify novel targets for these tumors. We show that loss of ATIP3 sensitizes breast cancer cells to WEE1 inhibition, resulting in aberrant mitoses characterized by detachment of centromere proteins from DNA and chromosome pulverization. This phenotype arises from excessive replication stress and DNA damage in S-phase, combined with premature mitotic entry driven by untimely CDK1 activation. Mechanistically, we identify DNA2 helicase/nuclease as a key mediator of chromosome pulverization. Importantly, the heightened sensitivity of ATIP3-deficient cells to WEE1 inhibition provides a strong rationale for clinical exploration of WEE1-targeted therapies. Furthermore, combining WEE1 and PKMYT1 inhibitors enhances therapeutic efficacy, offering a promising strategy for personalized treatment in ATIP3-deficient breast cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Université Paris-Saclay, 91400, Orsay, France.
- Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Université Paris-Saclay, 91400, Orsay, France; Inovarion, 75005, Paris, France.
- Translational Research Department, Institut Curie, PSL University, 75005, Paris, France.
- IKTOS, 75017, Paris, France.
- Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Université Paris-Saclay, 91400, Orsay, France. Electronic address: clara.nahmi…
Förderung
- La Ligue Contre Le Cancer
- Centre National de la Recherche Scientifique
- Institut National de la Santé et de la Recherche Médicale
- Fédération des GEFLUC
Zitieren
APA
Haykal, M. M., Rodrigues-Ferreira, S., El Botty, R., Sourd, L., Marangoni, E., Varin, M., Denis, A., & Nahmias, C. (2025). Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217665
Vancouver
Haykal MM, Rodrigues-Ferreira S, El Botty R, Sourd L, Marangoni E, Varin M, et al. Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217665
BibTeX
@article{Haykal2025,
author = {Haykal, Maria M and Rodrigues-Ferreira, Sylvie and El Botty, Rania and Sourd, Laura and Marangoni, Elisabetta and Varin, Marie and Denis, Alexis and Nahmias, Clara},
title = {Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217665}
}
EUVIMED